Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$12.95 - $49.69 $2.54 Million - $9.74 Million
-196,000 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$25.57 - $44.88 $5.01 Million - $8.8 Million
196,000 New
196,000 $8.8 Million

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.25B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Pinz Capital Management, LP Portfolio

Follow Pinz Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pinz Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Pinz Capital Management, LP with notifications on news.